FrancophonIA/ELRC3.0 huggingface dataset:
English: CRS is a side effect of certain cancer treatments and RoActemra is used for CRS caused by chimeric antigen receptors (CAR) T-cell medicines.
Estonian: RoActemrat kasutatakse kimäärse antigeeni retseptoreid ekspresseerivatel (CAR) T-rakkudel põhinevate ravimite põhjustatud tsütokiinide vabanemise sündroomi raviks.
English: In severe rheumatoid arthritis not previously treated with methotrexate, RoActemra given by infusion was investigated in one main study involving 1,162 patients.
Estonian: Varem metotreksaadiga ravimata raske aktiivse reumatoidartriidi korral uuriti infusiooniga manustatavat RoActemrat ühes põhiuuringus (1162 patsienti).
English: What benefits of RoActemra have been shown in studies?
Estonian: Milles seisneb uuringute põhjal RoActemra kasulikkus?
English: In juvenile idiopathic polyarthritis, RoActemra given by infusion was compared with placebo in one main study involving 166 children from 2 years of age who could not take methotrexate or it did not work well enough.
Estonian: Lapseea idiopaatilise polüartriidi ravis võrreldi infusiooniga manustatavat RoActemrat platseeboga ühes põhiuuringus, milles osales 166 vähemalt 2-aastast last, kellele metotreksaat ei sobinud või kelle ravivastus sellele oli ebapiisav.
English: After 6 months of treatment, 45% of patients taking RoActemra in combination with methotrexate (130 out of 290) and 39% of patients taking RoActemra on its own (113 out of 292) achieved remission (did not show symptoms of the disease), compared with 15% of those taking placebo plus methotrexate (43 out of 287).
Estonian: Pärast 6-kuulist ravi oli remissiooniga (sümptomiteta) patsiente RoActemra ja metotreksaadi kombinatsiooni uuringurühmas 45% (130 patsienti 290st), ainult RoActemrat kasutanute rühmas 39% (113 patsienti 292st) ning platseebo ja metotreksaadi kombinatsiooni rühmas 15% (43 patsienti 287st).
English: Results showed that patients adding RoActemra were around 4 times more likely to respond to treatment than those adding placebo.
Estonian: Patsientidel, kelle raviskeemi lisati RoActemra, tekkis ravivastus ligikaudu 4 korda suurema tõenäosusega kui patsientidel, kelle raviskeemi lisati platseebo.
English: • children from 1 year of age with active systemic juvenile idiopathic arthritis in whom other treatments (with anti-inflammatory medicines called NSAIDs and corticosteroids) have not worked well enough;
Estonian: • lapseea aktiivse idiopaatilise artriidi süsteemne vorm vähemalt 1-aastastel lastel, kellel ravi muude ravimitega (mittesteroidsed põletikuvastased ravimid (NSAID) ja kortikosteroidid) ei ole andnud
English: • adults with moderate to severe active rheumatoid arthritis whose previous treatments with disease modifying antirheumatic drugs (DMARDs), such as methotrexate or medicines known as tumour necrosis factor (TNF) blockers, have not worked well or were not tolerated;
Estonian: • mõõdukas kuni raske aktiivne reumatoidartriit täiskasvanutel, kellel varasem ravi haigust modifitseerivate antireumaatiliste ravimitega (nt metotreksaat või kasvaja nekroositeguri (TNF)
English: An overview of RoActemra and why it is authorised in the EU
Estonian: Ülevaade ravimist RoActemra ja ELis müügiloa väljastamise põhjendus
English: After 4 to 6 months of treatment, 26% of patients on RoActemra (21 out of 82) had a flare-up of symptoms during treatment, compared with 48% of patients taking placebo (39 out of 81).
Estonian: 4-6kuulise ravi järel oli ägenenud sümptomitega patsiente RoActemra uuringurühmas 26% (21 patsienti 82st) ja platseeborühmas 48% (39 patsienti 81st).
English: RoActemra can also be used in adults and children from 2 years of age for the treatment of severe or life-threatening cytokine release syndrome (CRS, a condition that can cause nausea, vomiting, pain and low blood pressure).
Estonian: RoActemrat võib kasutada ka täiskasvanutel ja vähemalt 2-aastastel lastel raske või eluohtliku tsütokiinide vabanemise sündroomi raviks.
English: In three of these studies, RoActemra was compared with placebo, as an add-on to failing treatment with conventional rheumatoid arthritis medicines in a total of over 3,000 patients.
Estonian: Neist kolmes võrreldi RoActemrat platseeboga, kasutades seda kokku üle 3000 patsiendil teiste reumatoidartriidi tavaravimitega tehtud ebaefektiivse ravi lisaravimina.
English: RoActemra is used in combination with methotrexate for these conditions but it can be used on its own in patients for whom methotrexate is inappropriate.
Estonian: Nende haiguste korral kasutatakse RoActemrat koos metotreksaadiga, aga kui patsiendile metotreksaat ei sobi, tohib RoActemrat kasutada ainsa ravimina.
English: RoActemra given by injection under the skin was investigated in two studies involving 1,918 patients with moderate to severe rheumatoid arthritis where previous treatment with DMARD had not worked well.
Estonian: Subkutaanse süstega manustatavat RoActemrat uuriti 2 uuringus, milles osales 1918 mõõduka kuni raske reumatoidartriidiga patsienti, kellel varasem ravi haigust modifitseerivate antireumaatiliste ravimitega ei andnud piisavaid tulemusi.
English: How RoActemra is given, its dose and how often it is given depends on the condition it is used to treat.
Estonian: RoActemra manustamisviis ja -sagedus ning annus sõltuvad ravitavast seisundist.
English: RoActemra is available as a solution to be injected under the skin and as a concentrate for making a solution for infusion (drip) into a vein.
Estonian: RoActemrat turustatakse subkutaanse süstelahusena ja infusioonilahuse (veeni tilgutatava lahuse) kontsentraadina.
English: In this study 85% (64 out of 75) patients treated with RoActemra responded to treatment and no longer had fever after 3 months, compared with 24% (9 out of 37) patients receiving placebo.
Estonian: Selles uuringus oli 3 kuu järel ravivastusega ja palavikuta patsiente RoActemra uuringurühmas 85% (64 patsienti 75st) ja platseeborühmas 24% (9 patsienti 37st).
English: RoActemra contains the active substance tocilizumab.
Estonian: RoActemra sisaldab toimeainena totsilisumaabi.
English: RoActemra is also used to treat adults with giant cell arteritis, a disease in which arteries, usually of the head, are swollen.
Estonian: RoActemrat kasutatakse ka hiidrakulise arteriidiga täiskasvanute raviks.
English: Tocilizumab attaches to the receptor for a messenger molecule or ‘cytokine' called interleukin-6.
Estonian: Totsilisumaab seondub virgatsaine tsütokiini interleukiin-6 retseptoriga.
English: • children from 2 years of age with juvenile idiopathic polyarthritis in whom treatment with methotrexate has not worked well enough.
Estonian: • lapseea idiopaatiline polüartriit vähemalt 2-aastastel lastel, kellel metotreksaatravi ei ole andnud
English: In giant cell arteritis, RoActemra given by injection under the skin was found more effective than placebo in one main study involving 251 adults.
Estonian: Põhiuuringus, milles osales 251 hiidrakulise arteriidiga täiskasvanut, oli subkutaanselt süstitav RoActemra efektiivsem kui platseebo.
English: Why is RoActemra authorised in the EU?
Estonian: ELis RoActemrale väljastatud müügiloa põhjendus
English: RoActemra given by infusion was considered to be effective at treating severe CRS based on a review of data from 66 patients who experienced this condition after they were given CAR-T cell medicines to treat a blood cancer.
Estonian: See järeldus tehti 66 patsiendi andmete läbivaatamise järel.
English: A second application is not recommended.
Estonian: Teistkordset kasutamist ei soovitata.
English: This summary was last updated in 12/2012.
Estonian: Kokkuvõtte viimane uuendus: 12/2012.
English: The European Commission granted a marketing authorisation valid throughout the European Union for NexoBrid on 18 December 2012.
Estonian: Euroopa Komisjon andis NexoBridi müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 18. detsembril 2012.
English: Other information about NexoBrid
Estonian: Muu teave NexoBridi kohta
English: In patients receiving NexoBrid, in around 15% (16 out of 106) of the wounds the eschar needed to be removed by surgery and around 18% (19 out of 106) required a skin graft, compared with around 63% (55 out of 88) and around 34% (30 out of 88) respectively in patients receiving standard debridement treatment.
Estonian: NexoBridi saavatest patsientidest umbes 15%l (16 osalejal 106st) tuli põletusraig kirurgiliselt eemaldada ja umbes 18% (19 osalejat 106st) vajas nahasiirdamist võrreldes vastavalt umbes 63%-ga (55 osalejat 88st) ning umbes 34%-ga (30 osalejat 88st) patsientidest, kes said nahakoe eemaldamise standardravi.
English: What measures are being taken to ensure the safe use of NexoBrid?
Estonian: Mis meetmed võetakse, et tagada NexoBridi kasutamise ohutus?
English: NexoBrid should be used within 15 minutes after mixing and should be left in contact with the skin for four hours.
Estonian: NexoBridi tuleb kasutada 15 minuti jooksul pärast segamist ja see jäetakse nahale neljaks tunniks.
English: It should only be used in specialised burns centres, and should not be applied to more than 15% of the patient's total body surface area.
Estonian: Ravimit tohib kasutada ainult spetsialiseeritud põletuskeskustes ja seda ei tohi kanda rohkem kui 15%-le patsiendi kehapindalast.
English: The company will also carry out a long-term study in adults and children comparing NexoBrid with standard debridement treatment to investigate the outcome of patients including cosmetic considerations.
Estonian: Ettevõte korraldab samuti pikaajalise uuringu täiskasvanutel ja lastel, mille käigus võrreldakse NexoBridi kahjustatud nahakoe eemaldamise standardraviga, et uurida patsientide ravi lõpptulemust, sealhulgas kosmeetilisest aspektist.
English: In addition, it was found that NexoBrid removed eschar from wounds faster than standard treatments.
Estonian: Peale selle leiti, et NexoBrid eemaldas põletusraia haavadelt kiiremini kui standardsed ravimeetodid.
English: It is available as a powder and gel, which are mixed together to make a gel (2 g/22 g or 5 g/55 g).
Estonian: Seda turustatakse pulbri ja geelina, mis segatakse kokku geeli saamiseks (2 g/22 g või 5 g/55 g).
English: The summary of the opinion of the Committee for Orphan Medicinal Products for NexoBrid can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Estonian: Harvikravimite komitee arvamuse kokkuvõte NexoBridi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
English: The company that markets NexoBrid must ensure that healthcare professionals in specialised burns centres who are expected to use NexoBrid receive appropriate training and an educational pack including a step-by-step guide to NexoBrid treatment, covering important safety considerations before and after using NexoBrid.
Estonian: NexoBridi turustav ettevõte peab tagama, et spetsialiseeritud põletuskeskuste tervishoiutöötajad, kes peavad oskama NexoBridi kasutada, saaksid sobiva väljaõppe ja koolituse, sealhulgas NexoBridiga teostatava ravi etapiviisilise juhise, mis hõlmab olulisi ohutusprobleeme enne ning pärast NexoBridi kasutamist.
English: NexoBrid was studied in one main study involving 156 patients, who were hospitalised with deep partial thickness or full thickness burn wounds.
Estonian: NexoBridi uuriti ühes põhiuuringus, milles osales 156 patsienti, kes said haiglaravi sügavate osaliselt ja kõiki nahakihte haaravate põletushaavade tõttu.
English: The full EPAR for NexoBrid can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst NexoBridi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Since some of the side effects seen, including delay in complete wound healing, may have been related to wound care procedures, the Committee decided that NexoBrid should only be used in specialised burns centres by healthcare professionals who have been trained to use it.
Estonian: Kuna mõned täheldatud kõrvalnähud, sealhulgas haava aeglane paranemine, võivad olla seotud haavaravi protseduuridega, otsustas inimravimite komitee, et NexoBridi tohivad kasutada ainult spetsialiseeritud põletuskeskuste tervishoiutöötajad, kes on saanud vastava väljaõppe.
English: The CHMP decided that NexoBrid's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et NexoBridi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: Deep partial thickness burns (sometimes called ‘second degree' burns) extend into a deep region of an inner layer of the skin called the dermis, while full thickness burns (sometimes called ‘third degree' burns) extend even deeper, through the whole dermis.
Estonian: Sügavad osaliselt nahakihte haaravad põletused (mida mõnikord nimetatakse teise astme põletusteks) ulatuvad naha dermise aluskihti, samas kui kõiki nahakihte haaravad põletused (mida mõnikord nimetatakse kolmanda astme põletusteks) ulatuvad veel sügavamale läbi kogu dermise.
English: What is NexoBrid?
Estonian: Mis on NexoBrid?
English: For more information about treatment with NexoBrid, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate NexoBridiga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: NexoBrid is applied to the area of burnt skin after the wound has been appropriately prepared.
Estonian: NexoBrid kantakse põlenud nahapiirkonnale pärast haava sobivat ettevalmistamist.
English: The Committee considered that NexoBrid was shown to be an effective debridement treatment with an acceptable safety profile which complements available surgical techniques.
Estonian: Komitee leidis, et NexoBrid on efektiivne kahjustatud koe eemaldamise meetod, mille ohutusprofiil on vastuvõetav ja mis täiendab olemasolevaid kirurgilisi tehnikaid.
English: The most commonly reported side effects with NexoBrid are local pain, and pyrexia (fever) or hyperthermia (high body temperature).
Estonian: NexoBridi kõige sagedamad teatatud kõrvalnähud on paikne valu ja palavik või hüpertermia (kõrge kehatemperatuur).
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for NexoBrid.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas NexoBridi kasutada.
English: What is the risk associated with NexoBrid?
Estonian: Mis riskid NexoBridiga kaasnevad?
English: This is a summary of the European public assessment report (EPAR) for NexoBrid.
Estonian: See on ravimi NexoBrid Euroopa avaliku hindamisaruande kokkuvõte.
English: For a burn wound area of 100 cm2, NexoBrid 2 g/20 g gel is used.
Estonian: 100 cm2 pindalaga haaval kasutatakse NexoBrid 2 g/20 g geeli.
English: NexoBrid must not be used in people who are hypersensitive (allergic) to the active substance, pineapples, papain (an enzyme found in papaya fruit) or any of the other ingredients.
Estonian: Nexobridi ei tohi kasutada patsiendid, kes on toimeaine, ananasside, papaiini (papaia viljas leiduv ensüüm) või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: Why has NexoBrid been approved?
Estonian: Miks NexoBrid heaks kiideti?
English: For a burn wound area of 250 cm2, NexoBrid 5 g/50 g gel is used.
Estonian: 250 cm2 pindalaga haaval kasutatakse NexoBrid 5 g/50 g geeli.
English: NexoBrid concentrate of proteolytic enzymes enriched in bromelain
Estonian: NexoBrid bromelaiinis rikastatud proteolüütiliste ensüümide kontsentraat
English: Because the number of patients with deep partial thickness and full thickness thermal burn wounds is low, the disease is considered ‘rare', and NexoBrid was designated an ‘orphan medicine' (a medicine used in rare diseases) on 30 July 2002.
Estonian: Et sügavate osaliselt ja kõiki nahakihte hõlmavate termiliste põletushaavadega patsientide arv on väike ja see haigus esineb harva, nimetati NexoBrid 30. juulil 2002 harvikravimiks.
English: The patients received either NexoBrid or standard debridement treatment (surgical or non-surgical treatments to remove the eschar) before receiving further treatment if required, such as surgery or a skin graft.
Estonian: Patsiendid said NexoBridi või nahakoe eemaldamise standardravi (kirurgiline või mittekirurgiline ravi põletusraia eemaldamiseks) enne edasist ravi, nagu operatsioon või nahasiirdamine.
English: NexoBrid is used in adults to remove eschar (dead tissue which is dried-out, thick, leathery and black) from deep partial thickness and full thickness burns of the skin caused by heat or fire.
Estonian: NexoBrid on näidustatud põletusraia (surnud kude, mis on kuivanud, tihe, nahkjas ja must) eemaldamiseks sügavate osaliselt ja kõiki nahakihte haaravate kuumusest või tulest põhjustatud põletushaavadega täiskasvanutel.
English: The results were also considered for burn wounds of all thicknesses, including full thickness wounds.
Estonian: Tulemusi vaadeldi ka kõigi sügavustega põletushaavade, sealhulgas kõiki nahakihte haaravate põletushaavade osas.
English: Removing the eschar helps to allow the living skin tissue to be treated and to heal.
Estonian: Põletusraia eemaldamine soodustab eluskoe ravi ja paranemist.
English: The main measure of effectiveness was the proportion of deep partial thickness wounds that needed surgery to remove further skin tissue or that required a skin graft from another area of the patient's body.
Estonian: Efektiivsuse põhinäitaja oli sügavate osaliselt nahakihte haaravate põletushaavade osakaal, mis vajasid operatsiooni edasiseks nahakoe eemaldamiseks või nahasiirdamist patsiendi keha muudest piirkondadest.
English: The CHMP noted the importance of prompt skin grafting of areas of full thickness and deep burn directly after debridement with NexoBrid, in line with the standard of care in European burns centres.
Estonian: Inimravimite komitee märkis kiire nahasiirdamise tähtsust kõiki nahakihte haaravate sügavate põletuste korral kohe pärast kahjustatud nahakoe eemaldamist NexoBridiga, kooskõlas Euroopa põletuskeskuste ravistandarditega.
English: The study showed that NexoBrid was more effective than standard of care treatment (surgical and non-surgical) at reducing the proportion of the deep partial thickness burn wounds that needed surgery to remove skin tissue or required a skin graft.
Estonian: Uuring näitas, et NexoBrid oli efektiivsem kui standardravi (kirurgiline ja mittekirurgiline) selliste sügavate osaliselt nahakihte haaravate põletushaavade osakaalu vähendamisel, mis vajasid operatsiooni nahakoe eemaldamiseks või nahasiirdamist.
English: For the full list of all side effects reported with NexoBrid, see the package leaflet.
Estonian: NexoBridi kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: NexoBrid is a medicine that contains the active substance ‘concentrate of proteolytic enzymes enriched in bromelain'.
Estonian: NexoBrid on ravim, mis sisaldab toimeainena bromelaiinis rikastatud proteolüütiliste ensüümide kontsentraati.
English: NexoBrid was also seen to be an effective debridement treatment for burn wounds of all thicknesses, including full thickness wounds.
Estonian: NexoBrid oli samuti efektiivne kahjustatud nahakoe eemaldamisel kõigi sügavustega põletushaavade, sealhulgas kõiki nahakihte haaravate põletushaavade korral.
English: The effects of NexoBrid were first tested in experimental models before being studied in humans.
Estonian: Enne inimuuringuid kontrolliti Nexobridi toimet muude katsetega.
English: What benefit has NexoBrid shown during the studies?
Estonian: Milles seisneb uuringute põhjal NexoBridi kasulikkus?
English: The CHMP concluded that NexoBrid effectively removes eschar from deep partial thickness and full thickness wounds and reduces the need for surgery to remove further skin tissue in deep partial thickness wounds.
Estonian: Inimravimite komitee järeldas, et NexoBrid eemaldab sügavatelt osaliselt ja kõiki nahakihte haaravatelt haavadelt efektiivselt põletusraia ning vähendab nahakoe eemaldamise operatsiooni vajadust sügavate osaliselt nahakihte haaravate põletushaavade korral.
English: How is NexoBrid used?
Estonian: Kuidas NexoBridi kasutatakse?
English: The active substance in NexoBrid is a mixture of enzymes extracted from the stem of the pineapple plant.
Estonian: NexoBridi toimeaine on ananassitaime tüveosast saadud ensüümide segu.
English: How does NexoBrid work?
Estonian: Kuidas NexoBrid toimib?
English: How has NexoBrid been studied?
Estonian: Kuidas NexoBridi uuriti?
English: This mixture of enzymes acts as a debriding agent, a substance used to remove dead tissue from areas of the skin such as burn wounds, by dissolving the burn wound eschar.
Estonian: Ensüümide segu lahustab põletushaava põletusraia ning seda kasutatakse kahjustatud nahakoe eemaldamiseks põletushaavadelt.
English: What is NexoBrid used for?
Estonian: Milleks NexoBridi kasutatakse?
English: The medicine can only be obtained with a prescription.
Estonian: NexoBrid on retseptiravim.
English: The maximum number of broachings should be limited to 20.
Estonian: Korgi läbistamiskordade maksimaalne arv ei tohi olla suurem kui 20.
English: PROHIBITION OF SALE, SUPPLY AND/OR USE Not applicable.
Estonian: MÜÜGI-, TARNIMISE JA/VÕI KASUTAMISE KEELD Ei rakendata.
English: Waste materials should be disposed of in accordance with local requirements.
Estonian: Jäätmed tuleb hävitada vastavalt kohalikule seadusandlusele.
English: The excipients listed in section 6.1 of the SPC are either allowed substances for which table 1 of the annex to Commission Regulation (EU) 37/2010 indicates that no MRLs are required or are considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this veterinary medicinal product.
Estonian: Abiained, mis on loetletud ravimi omaduste kokkuvõtte lõigus 6.1, on kas lubatud ained, millele Komisjoni määruse (EL) nr 37/2010 lisa tabelis 1 viidatakse kui ravimjääkide piirnorme mittenõudvatele, või Määruse (EÜ) nr 470/2009 reguleerimisalasse mittekuuluvad, kui neid kasutatakse nii nagu selles veterinaarravimis.
English: For lactating animals see section 4.11.
Estonian: Lakteerivate loomade kohta vt lõik 4.11.
English: BATCH NUMBER Lot: {number}
Estonian: PARTII NUMBER Lot:{number}
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 07-07-2009
Estonian: ESMASE MÜÜGILOA VÄLJASTAMISE / MÜÜGILOA UUENDAMISE KUUPÄEV Esmase müügiloa väljastamise kuupäev: 07-07-2009
English: It is recommended to administer the second injection at a different site since local tolerance has been assessed after single injection only.
Estonian: Teine süste soovitatakse teha muus kohas, sest paikset taluvust on hinnatud üksnes ühe süste järel.
English: Injection site swelling may be painful.
Estonian: Süstekoha paistetus võib olla valulik.
English: Pharmacotherapeutic group: Antiinflammatory and antirheumatic products, non-steroids (oxicams) ATCvet code: QM01AC06.
Estonian: Farmakoterapeutiline rühm: mittesteroidsed põletiku- ja reumavastased ained (oksikaamid) ATC-vet kood: QM01AC06
English: Macrogol 1500
Estonian: Makrogool 1500 Meglumiin Süstevesi
English: The active substance in Melovem is an allowed substance as described in table 1 of the annex to Commission Regulation (EU) No 37/2010:
Estonian: Toimeaine Melovem on Komisjoni määruse (EL) nr 37/2010 lisa tabelis 1 kirjeldatud lubatud aine: Farmakoloogilise toimega aine
English: When treating groups of animals, use a draw-off needle to avoid excessive broaching of the stopper.
Estonian: Loomarühmade ravimisel kasutage korginõela, et vältida korgi liigset läbistamist.
English: To obtain the best possible pain relieving effect post surgery Melovem should be administered 30 minutes before surgical intervention.
Estonian: Võimalikult efektiivse operatsioonijärgse valuvaigistava toime saavutamiseks tuleb Melovem manustada 30 minutit enne kirurgilist sekkumist.